Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease (vol 79, pg 555, 2019)

被引：1
|
作者：
Shirley, Matt [1 ]
机构：
[1] Springer, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2019年 / 79卷 / 07期
关键词：
D O I：
10.1007/s40265-019-01111-2
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The article Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
引用
收藏
页码：791 / 791
页数：1
相关论文
共 50 条
  • [41] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease (vol 46, pg 277, 2021)
    Rubino, Christopher M.
    Onufrak, Nikolas J.
    van Ingen, Jakko
    Griffith, David E.
    Bhavnani, Sujata M.
    Yuen, Dayton W.
    Mange, Kevin C.
    Winthrop, Kevin L.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (04) : 573 - 574
  • [42] SURVEY ON USE AND PERCEPTION OF AMIKACIN FOR TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE IN THE UK
    Obradovic, M.
    Van der Laan, R.
    Hale, J.
    Gerden, E.
    Musson, L.
    THORAX, 2021, 76 : A177 - A178
  • [43] Open-Label Trial of Amikacin Liposome Inhalation Suspension in M. Abscessus Lung Disease
    Siegel, S.
    Clock, J. A.
    Hoeft, J.
    Chan, B.
    Sullivan, P. E.
    Philley, J.
    Strnad, L. C.
    Griffith, D. E.
    Winthrop, K. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [44] The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
    Khan, Omer
    Chaudary, Nauman
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 2287 - 2294
  • [45] Open-Label Trial of Amikacin Liposome Inhalation Suspension in M. Abscessus Lung Disease
    Siegel, S.
    Clock, J. A.
    Hoeft, J.
    Chan, B.
    Sullivan, P.
    Philley, J.
    Strnad, L. C.
    Griffith, D. E.
    Winthrop, K. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [46] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
    Rubino, Christopher M.
    Onufrak, Nikolas J.
    van Ingen, Jakko
    Griffith, David E.
    Bhavnani, Sujata M.
    Yuen, Dayton W.
    Mange, Kevin C.
    Winthrop, Kevin L.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (02) : 277 - 287
  • [47] Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)
    Winthrop, K. L.
    Eagle, G.
    Thomson, R. M.
    Aksamit, T. R.
    Hasegawa, N.
    Morimoto, K.
    Addrizzo-Harris, D. J.
    O'Donnell, A. E.
    Marras, T. K.
    Flume, P. A.
    Loebinger, M. R.
    Morgan, L. C.
    Codecasa, L. R.
    Hill, A. T.
    Ruoss, S. J.
    Yim, J. J.
    Ringshausen, F. C.
    Field, S. K.
    Nezamis, J.
    Griffith, D. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [48] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
    Christopher M. Rubino
    Nikolas J. Onufrak
    Jakko van Ingen
    David E. Griffith
    Sujata M. Bhavnani
    Dayton W. Yuen
    Kevin C. Mange
    Kevin L. Winthrop
    European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46 : 277 - 287
  • [49] Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
    Christopher M. Rubino
    Nikolas J. Onufrak
    Jakko van Ingen
    David E. Griffith
    Sujata M. Bhavnani
    Dayton W. Yuen
    Kevin C. Mange
    Kevin L. Winthrop
    European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46 : 573 - 574
  • [50] A Randomized, Double-blind Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease to Validate Patient-reported Outcome Instruments and Assess Microbiological Outcomes of Treatment: The ARISE Study
    Daley, C. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
12345